On May 12, 2022, WHOﾒs COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement with the U.S. National Institutes of Health for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.

The licenses, which were transparented, global and non-exclusive, allowed manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries and help put an end to the pandemic.